SGLT-2抑制剂对糖尿病肾病影响的研究进展(5)
[26] ZHAO L L，MAKINDE E A，SHAH M A，et al.Rhinacanthins-rich extract and rhinacanthin C ameliorate oxidative stress and inflammation in streptozotocin-nicotinamide-induced diabetic nephropathy[J].J Food Biochem，2019，43(4)：e12812.
[27] GALLO L A，WARD M S，FOTHERINGHAM A K，et al.Erratum：Once daily administration of the SGLT2 inhibitor，empagliflozin，attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice[J].Sci Rep，2016，6：28124.
[28] BURKE K R，SCHUMACHER C A，HARPE S E.SGLT2 inhibitors：a systematic review of diabetic ketoacidosis and related risk factors in the primary literature[J].Pharmacotherapy，2017，37(2)：187-194.
[29] NADKARNI G N，FERRANDINO R，CHANG A，et al.Acute kidney injury in patients on SGLT2 inhibitors：a propensity-matched analysis[J].Diabetes Care，2017，40(11)：1479-1485.
[30] SHYANGDAN D S，UTHMAN O A，WAUGH N.SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus：a systematic review and network meta-analysis[J].BMJ Open，2016，6(2)：e009417.
(收稿日期：2020-06-15 修回日期：2020-06-24)
(編辑：潘明志), http://www.100md.com(蔡柳 李强翔)
[27] GALLO L A，WARD M S，FOTHERINGHAM A K，et al.Erratum：Once daily administration of the SGLT2 inhibitor，empagliflozin，attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice[J].Sci Rep，2016，6：28124.
[28] BURKE K R，SCHUMACHER C A，HARPE S E.SGLT2 inhibitors：a systematic review of diabetic ketoacidosis and related risk factors in the primary literature[J].Pharmacotherapy，2017，37(2)：187-194.
[29] NADKARNI G N，FERRANDINO R，CHANG A，et al.Acute kidney injury in patients on SGLT2 inhibitors：a propensity-matched analysis[J].Diabetes Care，2017，40(11)：1479-1485.
[30] SHYANGDAN D S，UTHMAN O A，WAUGH N.SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus：a systematic review and network meta-analysis[J].BMJ Open，2016，6(2)：e009417.
(收稿日期：2020-06-15 修回日期：2020-06-24)
(編辑：潘明志), http://www.100md.com(蔡柳 李强翔)